AHA 2026 Statistics Show CVD Deaths Declined for the First Time Since 2018
The AHA 2026 statistics report a 2.7% drop in U.S. cardiovascular deaths from 2022 to 2023 — the first decline since before the COVID-19 pandemic — even as hypertension, obesity, and cardiovascular-kidney-metabolic syndrome continue to climb. Persistent disparities and risk-factor trends in young adults are the headline concerns for family medicine.
The Story at a Glance:
- The AHA 2026 statistics report 915,973 U.S. cardiovascular deaths in 2023, down from 941,652 in 2022 and the first decline since 2018.
- Age-adjusted CVD mortality fell from 224.3 to 218.3 per 100,000 people.
- Heart disease remains the leading cause of U.S. death (22%); stroke moved up to fourth, displacing COVID-19.
- Hypertension affects 47.3% of adults; cardiovascular-kidney-metabolic (CKM) syndrome touches roughly 90%.
What the AHA 2026 Statistics Report
The AHA 2026 statistics, published in Circulation on January 21, 2026, documented the first decline in U.S. cardiovascular deaths since 2018, ending a five-year upward trend tied to COVID-19. Total CVD deaths fell from 941,652 in 2022 to 915,973 in 2023, with the age-adjusted rate dropping from 224.3 to 218.3 per 100,000 people.
The annual update — chaired by Latha P. Palaniappan, MD, MS, FAHA, and vice-chaired by Sadiya S. Khan, MD, MSc, FAHA — drew on 15 regional, national, and globally representative datasets. The report adds a new chapter on cardiovascular-kidney-metabolic (CKM) syndrome, a construct connecting heart disease, kidney disease, diabetes, and obesity that the writing group estimates affects roughly 90% of U.S. adults at some level.
Why It Matters for Family Medicine
For family medicine, the headline is mixed. Aggregate mortality is improving, but the conditions that drive cardiovascular disease — hypertension, obesity, diabetes, and sedentary behavior — keep moving the wrong way. Roughly half of U.S. adults still have some form of cardiovascular disease, a rate higher than before the pandemic.
Risk-factor signals in young adults are particularly concerning. The report highlights rising stroke incidence in the Southeast “Stroke Belt” and a near-universal CKM footprint that begins early — more than 80% of young and middle-aged adults already show metabolic, kidney, or cardiac risk markers.
Key Numbers from the AHA 2026 Statistics
The most actionable figures for primary care:
- Hypertension: 125.9 million U.S. adults (47.3%), up from 122.4 million (46.7%) in the prior period.
- Diabetes: 29.5 million diagnosed adults; only 43.5% of those treated for type 2 diabetes meet glycemic targets.
- Obesity: About 50% of adults overall; in youth ages 2–19, prevalence rose from 25.4% to 28.1%.
- Tobacco and nicotine: Cigarette smoking dropped to 7.9% of adults (from 10.8% in 2017), but adult e-cigarette use rose to 4.1% (from 1.2%); 18.1% of high schoolers use e-cigarettes.
- Physical activity: Only 25.3% of adults meet national activity guidelines.
- Life’s Essential 8: Ideal cardiovascular health is associated with a 74% lower risk of CVD events versus poor cardiovascular health.
What Experts Are Saying
Khan flagged risk-factor stagnation as the report’s most worrying signal, particularly the lack of progress on blood pressure, obesity, and diabetes among younger adults.
“These numbers should ring alarm bells, particularly among young adults.” — Sadiya S. Khan, MD, MSc, FAHA, Northwestern University Feinberg School of Medicine, vice-chair of the writing group
Palaniappan, the chair, framed the underlying-conditions burden as the larger story: nearly half of U.S. adults have some form of cardiovascular disease, a rate higher than before the pandemic. AHA volunteer president Stacey E. Rosen, MD, characterized the figures as a population-health imperative for primary care to convert into individual-level prevention.
What’s Next
The report flags several signals to watch through 2026 and beyond. The population-level impact of GLP-1 receptor agonists on CVD mortality remains uncertain, with the writing group noting encouraging trial-level data but unclear real-world reach. Real-world adoption of CKM staging is in early days. The AHA also expects further data on whether the post-COVID mortality recovery holds — or whether worsening risk-factor trends in young adults eventually reverse it.
Bottom Line
- Use the AHA 2026 statistics to frame visit-level CVD conversations — half of U.S. adults already have some form of cardiovascular disease.
- Tighten chronic-disease control: only 43.5% of patients treated for type 2 diabetes meet glycemic targets.
- Screen midlife patients for CKM syndrome using BP, albuminuria, eGFR, lipid panel, and A1c.
- Address rising e-cigarette use and Life’s Essential 8 metrics with adolescents and young adults.
Sources
- Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 2026;153(9):e275–e906. Circulation — Palaniappan et al., 2026 AHA Statistics Update
- American Heart Association. What the Latest Heart Disease and Stroke Numbers Mean for Your Health. January 21, 2026. AHA News — 2026 Statistics Highlights
- American Heart Association Professional Heart Daily. 2026 Heart Disease and Stroke Statistics — Science News. January 21, 2026. AHA Professional Heart Daily — 2026 Statistics Update
- American Heart Association. 2026 Heart Disease and Stroke Statistics Update At-a-Glance Fact Sheet. January 2026. AHA 2026 At-a-Glance Fact Sheet (PDF)
- Healio. Heart Disease Remains Leading Cause of Death, Despite Declining Overall Mortality. January 21, 2026. Healio — Khan Interview on the AHA 2026 Update
- Centers for Disease Control and Prevention. Heart Disease Facts. Updated January 2026. CDC — Heart Disease Facts
- Becker’s Cardiology. AHA’s 2026 Heart Disease and Stroke Report: 5 Things to Know. January 22, 2026. Becker’s Cardiology — 2026 AHA Report Summary